Back

Beam Therapeutics sues YolTech, Serapha over alleged stolen gene-editing trade secrets

Verifying
  • Beam Therapeutics sued YolTech Therapeutics and Serapha Bio over alleged trade-secret misuse.
  • $230 million supported Serapha’s AATD program after its agreement with YolTech.
  • Serapha plans a Phase 2/3 SERP-01 trial later this year or early 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.